Skip to main content
Signal8
Launch Terminal

ALX ONCOLOGY HOLDINGS INC (ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

NASDAQ:ALXOHealthcare
+0.00%$1.22
AH$1.19-2.46%vs close
Mkt Cap$152.41M
Float111.51M
O/S124.92M
Vol
$ Vol
RVOL
Inst Own84.2%
SI5.4%
Earnings
Dilution
ALX Oncology Holdings Inc. logoNASDAQ:ALXO$1.22+0.00%
Phase Distribution
9 lead-sponsored trials·5 active·2 completed
Phase 15
Phase 23
Phase 2/31
(4 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting3
Completed2
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Active, not recruiting

    A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

    Evorpacept (ALX148), Trastuzumab

    Gastric Cancer, Gastroesophageal Junction Adenocarcinoma +1

    Enrollment
    127
    Start
    Jan 2022
    Primary Completion
    May 2024
    Completion
    Jun 2026est.
    NCT05002127
  • Phase 2
    Active, not recruiting

    Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

    evorpacept, pembrolizumab

    Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

    Enrollment
    189
    Start
    Apr 2021
    Primary Completion
    Mar 2025
    Completion
    Jun 2026est.
    NCT04675294
  • Phase 2
    Active, not recruiting

    Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

    evorpacept, pembrolizumab

    Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

    Enrollment
    172
    Start
    May 2021
    Primary Completion
    Mar 2025
    Completion
    Jun 2026est.
    NCT04675333
  • Phase 2
    Recruiting

    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    Evorpacept (ALX148), Trastuzumab

    Breast Cancer, Metastatic

    Enrollment
    120
    Start
    Dec 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2028est.
    NCT07007559
  • Phase 1
    Completed

    A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

    Evorpacept (ALX148), Pembrolizumab

    Metastatic Cancer, Solid Tumor +2

    Enrollment
    174
    Start
    Feb 2017
    Primary Completion
    Feb 2022
    Completion
    Jul 2025
    NCT03013218
  • Phase 1
    Terminated

    A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

    evorpacept, azacitidine

    Higher Risk Myelodysplastic Syndromes

    Enrollment
    65
    Start
    Oct 2020
    Primary Completion
    Jan 2025
    Completion
    Jun 2025
    NCT04417517
  • Phase 1
    Terminated

    A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

    evorpacept, venetoclax

    Acute Myeloid Leukemia, AML, Adult

    Enrollment
    14
    Start
    May 2021
    Primary Completion
    May 2023
    Completion
    Aug 2023
    NCT04755244
  • Phase 1
    Completed

    A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

    Evorpacept, Enfortumab Vedotin

    Bladder Cancer, Urothelial Carcinoma

    Enrollment
    36
    Start
    Nov 2022
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05524545
  • Phase 1
    Recruiting

    A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

    ALX2004, ALX2004

    NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC +5

    Enrollment
    170
    Start
    Aug 2025
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2027est.
    NCT07085091
Search ClinicalTrials.gov for “Alx Oncology Holdings”